<span itemprop="author">G. van Londen, MD

Author's posts

FDA delays could end vital treatment for rare disease patients

The FDA is failing rare disease patients. I’m one of them. I’ve been on elamipretide for three years now. It is the only treatment that has made a meaningful difference in my life with primary mitochondrial myopathy—a degenerative genetic c…